ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO596

Impact of Elobixibat on Chronic Constipation in Patients on Hemodialysis Assessed Using the Patient Assessment of Constipation-Quality of Life Questionnaire

Session Information

Category: Health Maintenance, Nutrition, and Metabolism

  • 1300 Health Maintenance, Nutrition, and Metabolism

Authors

  • Kamei, Daigo, Tokyo Women's Medical University, Tokyo, Japan
  • Kamei, Yuiko, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
  • Nagano, Masashi, Nerima Sakuradai Clinic, Tokyo, Japan
  • Mineshima, Michio, Tokyo Women's Medical University, Tokyo, Japan
  • Nitta, Kosaku, Tokyo Women's Medical University, Tokyo, Japan
  • Tsuchiya, Ken, Tokyo Women's Medical University, Tokyo, Japan
Background

Hemodialysis patients are prone to constipation caused by fluid restriction, water removal, food restriction, complications, and drugs among other causes, and their quality of life (QOL) is adversely affected. Elobixibat is a highly selective inhibitor of an ileal bile acid transporter, leads to the augmentation of bile acid levels in the colon, and subsequently enhances colonic motility and secretion. Administration of elobixibat to hemodialysis patients with chronic constipation may improve QOL by a novel mechanism of action. However, the impact of elobixibat on chronic constipation in patients on hemodialysis has not been reported to date.
This study aimed to evaluate the effect of elobixibat on the QOL of hemodialysis patients with chronic constipation.

Methods

This was a multicenter study. We used the Japanese version of the Patient Assessment of Constipation-Quality of Life (PAC-QOL) questionnaire. Altogether, 26 patients (18 males and 8 females) aged from 47–90 years, who satisfied the Rome 3 diagnostic criteria for functional constipation were enrolled. These patients were additionally administered elobixibat 10 mg/day and responded to the PAC-QOL questionnaire at baseline and after 4 weeks. Bayesian statistics were used to confirm our results.

Results

The number of spontaneous bowel movements per week increased significantly from 2.5 ± 1.2 to 4.0 ± 2.0 (p <0.001). The Bristol Stool Form Scale score significantly improved from 1.8 ± 0.8 to 3.6 ± 0.7 (p <0.001).
The physical discomfort score decreased significantly from 1.92 ± 0.82 to 0.99 ± 0.74 (p <0.001). The psychosocial discomfort score decreased significantly from 1.19 ± 0.95 to 0.64 ± 0.60 (p <0.001). The worries/concerns and satisfaction scores also decreased significantly from 1.87 ± 0.75 to 1.28 ± 0.61 (p <0.001) and 2.80 ± 0.62 to 1.94 ± 0.79 (p <0.001), respectively. The total PAC-QOL score showed a significant decrease from 1.85 ± 0.69 to 1.18 ± 0.58 (p <0.001). Bayesian statistics confirmed the significance of these results.

Conclusion

Administration of elobixibat to hemodialysis patients with chronic constipation reduced the scores of PAC-QOL and improved the patients’ QOL. Elobixibat may therefore serve as a new option for the treatment of constipation in hemodialysis patients.